In HCS Pharma we strongly believe that 3D cell culture is the right way to improve drug dicovery processes. Moreover, we know that our 3D HydroscaffoldTM matrix BIOMIMESYS® could be useful for bioproduction. We will be happy to meet you at “8th Bioproduction congress“ on thursday and friday in Lyon, France. If Read more…
This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…
In HCS Pharma we strongly believe that 3D cell culture is the right way to improve drug dicovery processes. Moreover, we know that our 3D hydroscaffold matrix BIOMIMESYS® could be useful for bioproduction and then for cell therapy. We will be happy to meet you at ELRIG congress “Advancements in cell & Read more…
In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…
The Perseid meteor shower which is taking place on the 14th of July and will finish on the 1st September will reach its high point between the 10 and the 14th of August. Debris from comet Swift-Tuttle, which has broken off from its tail, is falling and should end its Read more…
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
We are happy to share that Nathalie Maubon, PhD, our CEO/CSO is currently attending BioAsia Taiwan, organized in Taipei. The event aims at building on the success of recent years’ gatherings to bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia, and explore business opportunities Read more…
Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, during which Julien could discuss with cancer researchers from all around the world. His poster Read more…
Chez HCS Pharma, nous sommes ravis de partager avec vous les avancées significatives que nous avons réalisées dans nos projets de recherche et développement. Avant de commencer, nous tenons à remercier “La Gazette du Laboratoire” pour leur soutien continu et leur couverture détaillée de nos efforts. Notre entreprise, basée à Read more…
We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
After Japan, the business trip has been been continued in Taïwan for several days! As a scientist, I was really happy to see such open-mind spirit when I present BIOMIMESYS technology and how this kind of technology will change the drug discovery process and help the cell therapy/regenerative medicine in Read more…
Last week, we had the pleasure to participate in the conference about Alternatives to Animal Experimentation which was held last week in Biocitech park, Romainville, France. It was organized by Adebiotech think tank, and gathered researchers from private companies and academia, and also people from organizations like FC3R and PETA Read more…
Nathalie, founder, CEO and CSO of HCS Pharma will be present in BIO international convention that takes place in Boston, USA from the 5th to the 8th of June. Is it the place to be for a start-up like HCS Pharma, proposing a breakthrough technology that will revolutionnize the biotechnology Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the dynamic scientific environment of Cambridge. Because this event was focusing on 3D cell culture, most Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
Zebrafish is a popular model organism for biomedical research worldwide beacause is an ideal model for studying embryonic development and genetic disorders. They have an impressive ability to regenerate damaged tissues, including fins, heart, and spinal cord. And that is why, we are very pleased to inform you that our Read more…
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, and personalized medicine. Recent advancements in organoid research have focused on improving their complexity and Read more…
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more about BIOMIMESYS®, an amazing and disruptive technology that reproduces all aspects of the microenvironment (matrix Read more…
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…